Ono Pharmaceutical Company, Ltd.
https://www.ono-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ono Pharmaceutical Company, Ltd.
US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
PRISM BioLab Completes Successful Tokyo IPO On Back Of Multiple Partnerships
The Japanese drug discovery bioventure builds on multiple alliances and an in-house platform to get away a successful IPO in Tokyo, which it will use to fund further pipeline and technology development.
CalciMedica Eyes Success In Pancreatitis, Acute Kidney Injury
Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
- Ono Pharmaceutical Co., Ltd.
- Ono Pharma Taiwan Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice